Equities Analysts Set Expectations for SWTX FY2024 Earnings

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) – Equities researchers at HC Wainwright dropped their FY2024 EPS estimates for shares of SpringWorks Therapeutics in a note issued to investors on Tuesday, November 12th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($3.03) per share for the year, down from their prior forecast of ($2.83). HC Wainwright currently has a “Buy” rating and a $74.00 target price on the stock. The consensus estimate for SpringWorks Therapeutics’ current full-year earnings is ($3.17) per share. HC Wainwright also issued estimates for SpringWorks Therapeutics’ Q4 2024 earnings at ($0.59) EPS, Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at $0.11 EPS and FY2025 earnings at ($0.65) EPS.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its earnings results on Tuesday, November 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.04. The firm had revenue of $49.10 million during the quarter, compared to analyst estimates of $53.28 million. SpringWorks Therapeutics had a negative net margin of 203.09% and a negative return on equity of 48.21%. The business’s revenue was up 4810.0% on a year-over-year basis. During the same period last year, the business earned ($1.27) earnings per share.

A number of other equities analysts have also recently issued reports on SWTX. JPMorgan Chase & Co. upped their price target on shares of SpringWorks Therapeutics from $64.00 to $68.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. Wedbush reiterated an “outperform” rating and issued a $77.00 target price on shares of SpringWorks Therapeutics in a research note on Thursday, November 7th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $68.17.

SpringWorks Therapeutics Trading Down 0.3 %

NASDAQ SWTX opened at $36.45 on Friday. SpringWorks Therapeutics has a 12 month low of $19.61 and a 12 month high of $53.92. The stock’s fifty day moving average price is $32.75 and its 200-day moving average price is $37.21. The stock has a market cap of $2.71 billion, a P/E ratio of -9.25 and a beta of 0.79.

Institutional Trading of SpringWorks Therapeutics

A number of large investors have recently made changes to their positions in the stock. Barclays PLC lifted its position in SpringWorks Therapeutics by 60.4% during the third quarter. Barclays PLC now owns 155,676 shares of the company’s stock valued at $4,987,000 after purchasing an additional 58,645 shares during the period. Main Management ETF Advisors LLC purchased a new stake in SpringWorks Therapeutics during the 3rd quarter valued at $746,000. Wellington Management Group LLP lifted its holdings in shares of SpringWorks Therapeutics by 5.6% during the 3rd quarter. Wellington Management Group LLP now owns 34,994 shares of the company’s stock valued at $1,121,000 after buying an additional 1,853 shares during the period. Soros Fund Management LLC boosted its stake in shares of SpringWorks Therapeutics by 45.3% in the 3rd quarter. Soros Fund Management LLC now owns 559,321 shares of the company’s stock worth $17,921,000 after buying an additional 174,321 shares during the last quarter. Finally, Quarry LP grew its holdings in shares of SpringWorks Therapeutics by 20.0% in the third quarter. Quarry LP now owns 6,000 shares of the company’s stock worth $192,000 after acquiring an additional 1,000 shares during the period.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.